Dihydroergotamine, a vasoactive drug used to treat migraine and cluster headaches, was developed in the mid-20th century and became widely used clinically in the 1950s and 1960s. Its history is marked by its effectiveness in acute migraine management but also by recognition of potential vasoconstrictive side effects, which necessitated careful patient selection and monitoring. Dihydroergotamine is included in various combination therapies for migraine prophylaxis and acute treatment. Its development highlighted the importance of dose regulation and monitoring cardiovascular effects to optimize efficacy while minimizing risks associated with systemic vasoconstriction.
BRAND NAMES
DHE 45 – commonly used injectable form
Migranal – nasal spray formulation
Dihydergot – oral or combination preparations in some countries.
MECHANISM OF ACTION
Dihydroergotamine is a semi-synthetic ergot alkaloid that acts primarily as a serotonin (5-HT) receptor agonist, especially at 5-HT1B and 5-HT1D receptors. Activation of these receptors causes cranial and cerebral blood vessel vasoconstriction, which helps relieve migraine attacks. Additionally, it inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings, reducing neurogenic inflammation associated with migraine pain.
PHARMACOKINETICS
Absorption
Dihydroergotamine is poorly absorbed orally, which limits its effectiveness when taken by mouth. It is more effectively administered via intranasal spray or parenteral routes (subcutaneous, intramuscular, or intravenous). After nasal administration, absorption is moderate but variable, with peak plasma concentrations typically reached within 30–60 minutes.
Distribution
Dihydroergotamine has a moderate volume of distribution, approximately 1–2 L/kg, indicating distribution into vascular tissues and peripheral organs. It is moderately bound to plasma proteins, which allows effective delivery to target sites such as cranial blood vessels and trigeminal nerve endings.
Metabolism
Dihydroergotamine is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. It undergoes first-pass metabolism when taken orally, which significantly reduces its systemic bioavailability.
Elimination
Dihydroergotamine is primarily eliminated via the liver, with biliary excretion being the main route, and a smaller portion is excreted in the urine as metabolites. The elimination half-life is approximately 9–13 hours, although this can vary depending on hepatic function and route of administration.
PHARMACODYNAMICS
Dihydroergotamine exerts its therapeutic effects primarily through agonism of 5-HT1B and 5-HT1D serotonin receptors, leading to cranial and cerebral vasoconstriction and reduction of neurogenic inflammation associated with migraine attacks. This dual action relieves headache pain and associated symptoms such as nausea and photophobia.
ADMINISTRATION
Dihydroergotamine can be administered via intranasal spray, subcutaneous, intramuscular, or intravenous injection depending on the severity and type of headache. Intranasal administration is commonly used for acute migraine attacks, while subcutaneous or intramuscular injections provide rapid relief in outpatient or emergency settings.
DOSAGE AND STRENGTH
dihydroergotamine is administered according to the route of administration and severity of the headache. The intranasal spray delivers 0.5 mg per spray, with 1–2 sprays per nostril at the onset of a migraine, which may be repeated after one hour, not exceeding 4 mg in 24 hours. Subcutaneous or intramuscular injections are given at 0.5–1 mg, repeated every 1–2 hours as needed, with a maximum of 3 mg per 24 hours.
DRUG INTERACTIONS
Dihydroergotamine can interact with other medications due to its vasoconstrictive effects and metabolism via CYP3A4. Strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and erythromycin, can increase plasma levels of dihydroergotamine, raising the risk of severe vasospasm, hypertension, or ergotism. Concomitant use with other vasoconstrictors, including triptans or sympathomimetics, may lead to additive cardiovascular effects and increased risk of myocardial or peripheral ischemia.
FOOD INTERACTIONS
Dihydroergotamine absorption is minimally affected by food, allowing it to be taken with or without meals, particularly for nasal or parenteral administration. However, excessive alcohol intake may enhance its vasoconstrictive effects, increasing the risk of dizziness, hypotension, or cardiovascular complications.
CONTRAINDICATIONS
Dihydroergotamine is contraindicated in patients with known hypersensitivity to ergot alkaloids. It should not be used in individuals with ischemic heart disease, uncontrolled hypertension, peripheral vascular disease, or cerebrovascular disease, as its vasoconstrictive effects may worsen these conditions.
SIDE EFFECTS
Nausea and vomiting
Dizziness or lightheadedness
Weakness or fatigue
Flushing.
OVER DOSAGE
Overdose of dihydroergotamine can lead to severe vasoconstriction, resulting in hypertension, chest pain, palpitations, dizziness, nausea, and vomiting. In extreme cases, it may cause peripheral ischemia, myocardial ischemia, or ergotism, which can threaten limb or organ viability.
TOXICITY
Dihydroergotamine toxicity arises mainly from excessive vasoconstriction, which can lead to hypertension, chest pain, palpitations, dizziness, and nausea. Severe or prolonged toxicity may result in peripheral ischemia, myocardial ischemia, or ergotism, potentially causing tissue damage. Chronic or repeated overuse can also increase the risk of rebound headaches or persistent vascular complications.
